Parexel Builds Momentum, Boosts 2008 Outlook

Tuesday, January 29, 2008 09:47 AM

Parexel, a global contract research organization (CRO), continues on a nice roll with its shares up another 1.7% yesterday to $57—just off its 52-week high.

Last week when Parexel reported strong earnings, its shares got a hefty pop. That good news came after Mad Money host Jim Cramer gave the contract research sector a thumbs up on Jan. 14, noting Parexel’s strength in late phase work.

In its second quarter reported Jan. 23, Parexel said net income jumped 27% to $11.5 million, or 40 cents a share, from $9.08 million, or 32 cents a share, in the year ago period. Revenue increased 29% to $284.3 million.

Josef H. von Rickenbach, Parexel’s chairman and chief executive officer, noted, "During the second quarter, very strong revenue growth was driven by increases across all business and geographic reporting segments. The quarter's operating performance further validates our strategy and tangibly demonstrates that the initiatives we have been focusing on over the past few years are bearing fruit. In combination with the current favorable outsourcing market, our proven capabilities to compete for and win significant levels of new business leaves us well-positioned to further improve operating margins and drive profitable growth.”

For its third quarter, the company expects earnings of 42 cents to 44 cents a share on  revenue of $240 million to $250 million.

For  fiscal 2008, Parexel boosted guidance to $1.78 to $1.83 a share from $1.75 to $1.81 a share. Parexel also adjusted upward its revenue range to $935 million to $955 million, from $890 million to $920 million.

Parexel’s backlog rose 41% year-over-year to $1.778 billion as of Dec. 31, 2007.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs